James J Morton, MD | |
8600 Old Georgetown Rd, Bethesda, MD 20814-1422 | |
(301) 896-3100 | |
(301) 896-2393 |
Full Name | James J Morton |
---|---|
Gender | Male |
Speciality | Critical Care (intensivists) |
Experience | 26 Years |
Location | 8600 Old Georgetown Rd, Bethesda, Maryland |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1114975778 | NPI | - | NPPES |
19460025 | Other | DC | CAREFIRST BCBS |
769702301 | Medicaid | MD | |
026674400 | Medicaid | DC | |
61086004 | Other | MD | CAREFIRST BCBS |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207RC0200X | Internal Medicine - Critical Care Medicine | D0055612 (Maryland) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Medstar Montgomery Medical Center | Olney, MD | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Mgmc Llc | 9537073119 | 412 |
News Archive
The U.S. Food and Drug Administration has approved the first ablation catheters for the treatment of atrial fibrillation (uncoordinated contractions of the upper heart chambers), one of the most common types of arrhythmias-or abnormal heart rhythms-affecting more than two million Americans.
Women of color face both racial and gender disparities in the incidence, onset, and outcomes of diseases as diverse as cancer, cardiovascular disease, HIV infection and age-related disability.
Among patients with both heart failure and atrial fibrillation (AFib), treatment strategies focused on controlling the heart rhythm (using catheter ablation) and those focused on controlling the heart rate (using drugs and/or a pacemaker) showed no significant differences in terms of death from any cause or progression of heart failure.
Santarus, Inc. and VeroScience LLC today announced that analyses of 379-patient subset data from a 3,070-patient Phase III safety study conducted with CYCLOSET (bromocriptine mesylate) tablets suggested that CYCLOSET as an add-on to oral antidiabetes drugs produced improvements in glycemic control irrespective of baseline duration of disease.
› Verified 2 days ago
Entity Name | Mgmc Llc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1891797148 PECOS PAC ID: 9537073119 Enrollment ID: O20031220000056 |
News Archive
The U.S. Food and Drug Administration has approved the first ablation catheters for the treatment of atrial fibrillation (uncoordinated contractions of the upper heart chambers), one of the most common types of arrhythmias-or abnormal heart rhythms-affecting more than two million Americans.
Women of color face both racial and gender disparities in the incidence, onset, and outcomes of diseases as diverse as cancer, cardiovascular disease, HIV infection and age-related disability.
Among patients with both heart failure and atrial fibrillation (AFib), treatment strategies focused on controlling the heart rhythm (using catheter ablation) and those focused on controlling the heart rate (using drugs and/or a pacemaker) showed no significant differences in terms of death from any cause or progression of heart failure.
Santarus, Inc. and VeroScience LLC today announced that analyses of 379-patient subset data from a 3,070-patient Phase III safety study conducted with CYCLOSET (bromocriptine mesylate) tablets suggested that CYCLOSET as an add-on to oral antidiabetes drugs produced improvements in glycemic control irrespective of baseline duration of disease.
› Verified 2 days ago
Entity Name | Johns Hopkins Community Physicians |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1255359972 PECOS PAC ID: 8325943707 Enrollment ID: O20040130000162 |
News Archive
The U.S. Food and Drug Administration has approved the first ablation catheters for the treatment of atrial fibrillation (uncoordinated contractions of the upper heart chambers), one of the most common types of arrhythmias-or abnormal heart rhythms-affecting more than two million Americans.
Women of color face both racial and gender disparities in the incidence, onset, and outcomes of diseases as diverse as cancer, cardiovascular disease, HIV infection and age-related disability.
Among patients with both heart failure and atrial fibrillation (AFib), treatment strategies focused on controlling the heart rhythm (using catheter ablation) and those focused on controlling the heart rate (using drugs and/or a pacemaker) showed no significant differences in terms of death from any cause or progression of heart failure.
Santarus, Inc. and VeroScience LLC today announced that analyses of 379-patient subset data from a 3,070-patient Phase III safety study conducted with CYCLOSET (bromocriptine mesylate) tablets suggested that CYCLOSET as an add-on to oral antidiabetes drugs produced improvements in glycemic control irrespective of baseline duration of disease.
› Verified 2 days ago
Mailing Address | Practice Location Address |
---|---|
James J Morton, MD Po Box 791372, Baltimore, MD 21279-1372 Ph: (301) 608-8375 | James J Morton, MD 8600 Old Georgetown Rd, Bethesda, MD 20814-1422 Ph: (301) 896-3100 |
News Archive
The U.S. Food and Drug Administration has approved the first ablation catheters for the treatment of atrial fibrillation (uncoordinated contractions of the upper heart chambers), one of the most common types of arrhythmias-or abnormal heart rhythms-affecting more than two million Americans.
Women of color face both racial and gender disparities in the incidence, onset, and outcomes of diseases as diverse as cancer, cardiovascular disease, HIV infection and age-related disability.
Among patients with both heart failure and atrial fibrillation (AFib), treatment strategies focused on controlling the heart rhythm (using catheter ablation) and those focused on controlling the heart rate (using drugs and/or a pacemaker) showed no significant differences in terms of death from any cause or progression of heart failure.
Santarus, Inc. and VeroScience LLC today announced that analyses of 379-patient subset data from a 3,070-patient Phase III safety study conducted with CYCLOSET (bromocriptine mesylate) tablets suggested that CYCLOSET as an add-on to oral antidiabetes drugs produced improvements in glycemic control irrespective of baseline duration of disease.
› Verified 2 days ago
Ardalan Enkeshafi, M.D. Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 6410 Rockledge Dr Ste 304, Bethesda, MD 20817 Phone: 443-602-6207 | |
Dr. Tara Palmore, M.D. Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 10 Center Dr, Msc 1888, Bethesda, MD 20892 Phone: 301-496-4000 | |
Dr. Cornelia Diana Cudrici, M.D. Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 10 Center Drive Bld 10 Rm 6n216a, Bethesda, MD 20892 Phone: 301-443-5519 | |
Shanthi Murgesh Nadar, Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 8600 Old Georgetown Road, Bethesda, MD 20814 Phone: 301-896-3100 | |
Dr. Nicole Jeanine Gormley, M.D. Critical Care Medicine Medicare: Not Enrolled in Medicare Practice Location: 10 Center Dr, Bldg 10, Rm 2c145, Bethesda, MD 20892 Phone: 301-496-9320 | |
Dr. Harshkumar Patel, MBBS Critical Care Medicine Medicare: Not Enrolled in Medicare Practice Location: 10 Center Dr, Bethesda, MD 20892 Phone: 301-496-9320 Fax: 301-402-1213 | |
Dr. Tung N Dao, M.D. Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 6410 Rockledge Dr, Ste 200, Bethesda, MD 20817 Phone: 301-897-5301 Fax: 301-564-4289 |